Android app Apple app link

Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial

By Yahoo! Finance   |   4 weeks ago
Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial

Outlook Therapeutics faces setback as its wet AMD therapy, Lytenava, failed to meet a key endpoint in Phase III trial. Despite this, the company plans to resubmit for US approval in Q1 2025, aiming to address FDA concerns and pursue global partnerships.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.